Abstract |
The patient was a 62-year-old man with small-cell lung cancer (limited disease). He was treated with cisplatin (CDDP) plus etoposide(ETP) and concurrent radiotherapy as first-line treatment. Although a complete response was achieved, his pro-GRP elevated 10 months later. He was treated with several anticancer agents including, CDDP plus irinotecan (CPT-11), CPT-11, paclitaxel and amrubicin (AMR). Although, as a monotherapy, the administration of AMR (30 mg/m(2)) for 3 consecutive days (3-day schedule) seemed to be most effective, severe myelosuppression was observed, and this treatment was discontinued. We changed the treatment schedule to biweekly administration of AMR (30 mg/m(2)). The level of pro-GRP decreased, and it was maintained at a similar level for 7 months. No severe toxicity was observed during this period. This case suggests that the bi-weekly administration of AMR may be a useful option for the treatment of small-cell lung cancer when a 3-day AMR schedule is highly myelosuppressive.
|
Authors | Jun Kurai, Tadashi Igishi, Hisashi Suyama, Masahiro Kodani, Yasushi Fukuoka, Masanori Miyata, Hirokazu Touge, Yasuaki Hasegawa, Kazuto Yasuda, Yutaka Hitsuda, Eiji Shimizu |
Journal | Gan to kagaku ryoho. Cancer & chemotherapy
(Gan To Kagaku Ryoho)
Vol. 33
Issue 3
Pg. 373-5
(Mar 2006)
ISSN: 0385-0684 [Print] Japan |
PMID | 16531722
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Anthracyclines
- Etoposide
- Irinotecan
- amrubicin
- Cisplatin
- Camptothecin
|
Topics |
- Anthracyclines
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Bone Marrow
(drug effects)
- Camptothecin
(administration & dosage, analogs & derivatives)
- Carcinoma, Small Cell
(drug therapy)
- Cisplatin
(administration & dosage)
- Drug Administration Schedule
- Etoposide
(administration & dosage)
- Humans
- Irinotecan
- Lung Neoplasms
(drug therapy)
- Male
- Middle Aged
|